We are international
• about myeloma TEXT SIZE   

Myeloma Minute
August 15, 2013
August 15, 2013
Share the Minute Facebook Tweet!
Clinical Trials
Donate to the IMF

Watch this week's episode
of #AskDr.Durie, the IMF's weekly web series

Upcoming Events

Saturday, November 9, 2013
IMF’s 7th Annual Comedy Celebration

Saturday, October 12, 2013
St. Louis Regional Community Workshop
St. Louis, Missouri
Myeloma Drug Approvals in Europe Bring More Options for Patients
Last week, the European Medicines Agency (EMA) approved pomalidomide (Imnovid® in Europe and Pomalyst® in the US) for myeloma patients who have exhausted other treatment options. Pomalidomide had not previously been approved for patients in Europe. The EMA also expanded approval of bortezomib (Velcade®) for previously untreated patients before stem cell transplantation. Both drugs are approved for these uses in the US. Following these approvals in Europe, the next step is reimbursement approvals in each country to allow myeloma patients to access the drugs. Susie Novis, President and Co-founder of the IMF, commented: "We understand the need among patients in Europe, and through the IMF's global advocacy arm, are working to ensure the best outcomes possible for patients there and around the world." READ MORE
Exploring the Possible Hidden Factors in Weight Gain
We are all aware that a high percentage of US citizens are overweight. This is an important topic for myeloma patients because several studies have linked excess weight to an increased risk of myeloma. But, as IMF Chairman Dr. Brian Durie writes in his blog, a study notes that not only are people getting fatter, but so are animals in the wild, laboratory animals, and even pets. What's going on? READ MORE
The IMF Hits the Windy City to Inform and Empower Myeloma Patients
The International Myeloma Foundation hosted another successful Patient & Family Seminar in Chicago last weekend, welcoming approximately 170 patients and caregivers for the two-day sessions designed to inform and empower patients with multiple myeloma. It had been a few years since our last seminar in the Midwest – and the positive feedback we received from many of our first-time attendees reminds us why these seminars are so important to the myeloma community. With one final seminar for 2013 coming up in Philadelphia next week, we are already looking at possible locations for 2014!
IMF's Advocacy Efforts Highlighted in Video Interview
Meghan Buzby, Director of US Advocacy for the IMF, tells Patient Power in this video interview what myeloma patients can do to help all patients access oral anticancer treatments. She explains that insurance reimbursement issues can create high out-of-pocket costs for patients. Meghan notes, "it is so important for patients to reach out to their legislators because their personal stories are what the legislator is going to connect with." VIEW VIDEO HERE | VISIT THE IMF'S ACTION CENTER HERE

Join Our Mailing List

12650 Riverside Drive, Suite 206 | North Hollywood, CA 91607-3421
IMF Hotline: 800-452-2873 or 818-487-7455
Privacy Policy | Unsubscribe 

 related articles